Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.80 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | BLVRB | P30043 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373472 | 0.89 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12373475 | 0.88 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12373479 | 0.85 | XDH (0.72) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL1986815 | 0.85 | XDH (0.77) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL3703625 | 0.81 | XDH (0.72) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL3709865 | 0.79 | XDH (0.63) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL3705198 | 0.76 | XDH (0.64) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL3711105 | 0.76 | XDH (0.72) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL1988257 | 0.75 | XDH (0.71) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL1983504 | 0.74 | XDH (0.65) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2338887-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010044404-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | キッセイ薬品工業株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | XDH 1/4885TARBP2 4138/4885ABCC4 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.